Entospletinib, also known as GS-9973, is a highly selective and orally efficacious Syk inhibitor which is currently undergoing clinical evaluation for autoimmune and oncology indications. In Phase II clinical trials, Entospletinib demonstrates clinical activity in subjects with relapsed or refractory CLL with acceptable toxicity.
仅供研究使用。 我们不向患者出售。
化学信息
名称 | Entospletinib (GS-9973) |
Iupac 化学名称 | 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine |
同义词 | Entospletinib; GS9973; GS 9973; GS-9973. |
英文同义词 | Entospletinib; GS9973; GS 9973; GS-9973. |
分子式 | C23H21N7O |
分子量 | 411.46 |
Smile | N1N=CC2=CC=C(C=C12)C=1N=C(C=2N(C1)C=CN2)NC2=CC=C(C=C2)N2CCOCC2 |
InChiKey | XSMSNFMDVXXHGJ-UHFFFAOYSA-N |
InChi | InChI=1S/C23H21N7O/c1-2-17-14-25-28-20(17)13-16(1)21-15-30-8-7-24-23(30)22(27-21)26-18-3-5-19(6-4-18)29-9-11-31-12-10-29/h1-8,13-15H,9-12H2,(H,25,28)(H,26,27) |
Cas号 | 1229208-44-9 |
相关CAS号 | |
外观性状 | Solid powder |
纯度 | 98% by HPLC |
存储 | -20 ºC for 3 years |
可溶性 | Soluble in DMSO |
处理方式 | |
运输条件 | Shipped under ambient temperature |
海关编码 | |
Targets | |
Mechanism | |
Cell study | |
Animal study | |
Clinical study | |